JUPITER LIFE LINE HOSPITALS SEES 23% GROWTH IN Q2 CONSOLIDATED EBITDA; RECOMMENDATION REMAINS 'BUY' |

In a recent report released by Prabhudas Lilladher, analysts have expressed optimism over Jupiter Life Line Hospitals (JLHL) following the release of its Q2 consolidated EBITDA results. The company's Q2 EBITDA grew by 23% on a year-on-year basis to Rs. 750 million.

This growth momentum is largely attributed to higher Average Revenue Payable Outstanding Balance (ARPOB) and occupancy rates in the competitive markets operated by JLHL, particularly in Mumbai Metropolitan Region (MMR). With the company's strong operational efficiency marked across these markets, JLHL has witnessed a revenue/EBITDA CAGR of 24% over FY21-24.

Looking forward to the long term, analysts see Jupiter Life Line Hospitals continuing its growth trajectory at an EBITDA and PAT CAGR of 21% and 19%, respectively, from FY24 to FY27E. Additionally, return ratios are expected to be around 20%.

Following these positive projections, Prabhudas Lilladher has maintained its 'Buy' rating for JLHL shares, valuing them at a price-to-earnings (P/E) ratio of 25 by the end of FY27E based on its EBITDA. The analysts have set an updated target price of Rs1,660/share.

The market response to these projections will be keenly watched in the days ahead as JLHL continues to drive growth momentum with its strategic expansions and scale-ups across western regions.